Mucosis

company

About

Mucosis is a clinical stage Dutch biotechnology company developing mucosal vaccines.

  • 1 - 10

Details

Last Funding Type
Series A
Last Funding Money Raised
€3M
Industries
Biotechnology,Health Care,Medical
Founded date
Jan 1, 2006
Number Of Employee
1 - 10
Operating Status
Active

Mucosis B.V. is a clinical stage Dutch biotechnology company developing innovative mucosal vaccines that can be applied needle-free via the nose or mouth. Mucosis’s lead product candidate is SynGEM:registered:, an intranasal vaccine to prevent respiratory syncytial virus infection.

Mucosis' vaccines are based on the patented and validated Mimopath:registered: technology. This technology enables a more natural immune response as well as a broad base of protection as was seen in their proof-of-concept animal and human studies of their FluGEM:registered: vaccine candidate.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
€3M $6.90M
Mucosis has raised a total of €3M $6.90M in funding over 2 rounds. Their latest funding was raised on Apr 29, 2014 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Apr 29, 2014 Series Unknown $6.90M 1 Detail
Sep 10, 2007 Series A €3M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Mucosis is funded by 1 investors. MedSciences Capital are the most recent investors.
Investor Name Lead Investor Funding Round
MedSciences Capital Series Unknown